Clinical trial
Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS)…
NCT00414310 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00414310 |
|---|---|
| Title | Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) |
| Official title | Phase II Randomized Study of Low-Dose Decitabine (5-AZA-2'-Deoxycytidine) With or Without Valproic Acid in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia -"SPORE" |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Eisai Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome, Acute Myelogenous Leukemia |
| Intervention type | Drug |
| Interventions | Decitabine, Valproic Acid |
| Enrollment | 153 |
| Start date | Dec 1, 2006 |
| Primary completion | May 1, 2015 |
| Completion | May 1, 2015 |
| First posted | Dec 21, 2006 |
| Last update posted | May 21, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: